Document Detail

Kinase dysfunction and kinase inhibitors.
MedLine Citation:
PMID:  23331696     Owner:  NLM     Status:  In-Data-Review    
With recent advances in molecular biology, abnormalities in cancer cells that contribute to dysregulation of cell survival and proliferation are being characterized with greater precision. Through this process, key abnormalities in cancer cells involving proteins that regulate signal transduction, migration, mitosis and other critical processes have been identified. Such abnormalities often involve a class of proteins called kinases that act to phosphorylate other proteins in the cell, resulting in activation of these proteins in the absence of appropriate stimulation/regulation. Given their role in tumour biology, substantial effort has been directed at blocking the function of these proteins. Several approaches have been used, including monoclonal antibodies and small molecule inhibitors. While antibodies are primarily directed at cell surface proteins, small molecule inhibitors, also known as kinase inhibitors, target proteins throughout the cell. A variety of kinase inhibitors have been approved for the treatment of human cancers. In some instances, these inhibitors have exhibited significant clinical efficacy, and it is likely that their biological activity will be further enhanced as combination regimens with standard treatment modalities are explored. The use of kinase inhibitors in dogs and cats is relatively recent, although two inhibitors, toceranib (Palladia; Pfizer Animal Health, Madison, NJ, USA) and masitinib (Kinavet; Catalent Pharma Solutions, Somerset, NJ, USA) have been approved by the Federal Drug Administration (USA) for use in dogs. This article reviews the biology of protein kinase dysfunction in human and animal cancers, and the application of specific kinase inhibitors to veterinary cancer patients.
Cheryl A London
Related Documents :
16158186 - Regulation of the extracellular signal-regulated kinases following acute and chronic op...
18716286 - Regulation of intracellular signaling cascades by gnrh pulse frequency in the rat pitui...
24029226 - Mechanisms of targeted therapy resistance take a de-tor.
9582336 - Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondr...
16933466 - Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis.
22367616 - Association between a casein kinase 1 epsilon gene polymorphism and schizophrenia in a ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Veterinary dermatology     Volume:  24     ISSN:  1365-3164     ISO Abbreviation:  Vet. Dermatol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9426187     Medline TA:  Vet Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  181-e40     Citation Subset:  IM    
Copyright Information:
© 2013 The Author. Veterinary Dermatology © 2013 ESVD and ACVD.
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43214, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advances in the management of skin cancer.
Next Document:  The contribution of stem cells to epidermal and hair follicle tumours in the dog.